🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Treace Medical Concepts, Inc. TMCI R2K

Healthcare · Medical Devices · United States
https://www.treace.com

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

READ MORE ›
$3.46
-39.72% 1Y

Market & Price

Market Cap
$224.46M
Current Price
$3.46
High / Low (52W)
$7.70 / $1.20
Beta
1.11

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.19
Price to Book
2.91
P/S
1.08
EV/EBITDA
-5.12
Dividend Yield
-

Profitability & Returns

ROCE
-33.56%
ROE
-66.88%
ROA
-17.87%
Profit Margin
-29.44%
Op Margin
-36.37%
EPS (Latest Qtr)
$-0.28
EPS (TTM)
$-0.96

Balance Sheet & Liquidity

Debt/Equity
0.93
Quick Ratio
2.40
Current Ratio
3.58
Debt
$71.60M
Total Assets
$190.58M
Current Assets
$132.05M
Working Capital
$101.42M

Ownership

Promoter Holding
25.43%
Chg in Prom Hold
0.18%
FII / Inst Holding
57.10%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$244.21M
Total Revenue (TTM)
$207.32M
EBITDA
$-47.68M
Free Cash Flow
$-5.77M
Operating Cash Flow
$-12.93M
Shares Outstanding
64.87M
Gross Margin
79.72%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
14.46%
Profit 5Y
-12.60%
Revenue (YoY)
-10.20%
Earnings (YoY)
-

PROS

  • Compounding revenue at 14.5% over 5 years.

CONS

  • Earnings shrank at -12.6% CAGR over 5 years.
  • Trading 55.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).
  • RSI at 82 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TMCI Treace Medical Concepts, Inc. R2K 3.46 - $224.46M - -33.56% -66.88% 14.46% -12.60%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 11.26M7.74M14.27M18.71M20.65M21.62M29.05M29.97M33.05M42.20M41.95M40.76M51.11M44.45M45.09M52.57M47.39M50.21M62.52M47.20M
Cost of Revenue ---------------10.68M9.63M10.51M12.12M9.79M
Gross Profit 8.87M5.65M11.36M15.38M16.71M17.37M23.92M24.68M26.96M34.16M34.28M32.76M40.98M35.67M36.13M41.89M37.75M39.71M50.40M37.41M
Operating Expenses ---------------57.48M54.73M55.38M56.32M54.57M
Operating Income -1.20M-1.52M-63.00K-1.40M-4.05M-5.46M-8.10M-11.93M-11.32M-13.78M-13.05M-17.82M-18.97M-21.38M-15.13M-15.58M-16.97M-15.68M-5.92M-17.17M
EBITDA ----------------12.15M-13.50M-12.17M-5.24M-15.49M
Interest Expense ---------------1.31M1.32M1.34M1.35M1.57M
Pretax Income ----------------15.92M-17.40M-16.29M-9.39M-17.96M
Tax Provision --------------------
Net Income -1.61M-1.97M-2.65M-2.43M-5.08M-6.42M-9.04M-17.23M-12.13M-13.45M-12.27M-17.52M-18.68M-21.21M-15.36M-15.92M-17.40M-16.29M-9.39M-17.96M
Diluted EPS -----0.10-0.12-0.16-0.31-0.22-0.23-0.20-0.28-0.30-0.34-0.25-0.25-0.28-0.26-0.15-0.28
R&D Expense 1.43M982.00K1.51M1.87M2.42M2.54M3.05M2.98M3.80M3.41M3.53M4.35M5.26M5.16M4.96M5.56M5.50M4.68M-4.62M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 39.42M57.37M-141.84M187.12M209.36M212.69M
Cost of Revenue ---25.53M35.18M41.09M42.94M
Gross Profit 31.79M44.90M-116.31M151.94M168.26M169.75M
Operating Expenses ---151.15M203.37M223.95M223.91M
Operating Income -3.54M855.00K--34.84M-51.43M-55.69M-54.15M
EBITDA ----36.28M-39.01M-42.07M-43.06M
Interest Expense ---4.40M5.17M5.26M5.32M
Pretax Income ----42.81M-49.53M-55.74M-59.00M
Tax Provision -------
Net Income -4.26M-3.67M--42.81M-49.53M-55.74M-59.00M
Diluted EPS --0.12-0.43-0.77-0.81-0.90-
R&D Expense 5.07M5.85M10.20M13.58M15.44M20.59M20.28M

Compounded Sales Growth

5 Years:14.46%
1 Year:-10.20%

Compounded Profit Growth

5 Years:-12.60%
1 Year:-

Stock Price Performance

1 Year:-39.72%
6 Months:+11.97%
3 Months:+86.02%
1 Month:+94.38%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --41.81M-159.02M251.91M217.09M190.58M
Current Assets ----133.40M198.36M161.40M132.05M
Cash & Equivalents 1.28M12.14M18.08M-19.47M12.98M11.35M10.71M
Inventory ----19.33M29.25M39.26M36.03M
Receivables ----29.20M38.06M40.80M42.16M
Total Liabilities --41.03M-98.50M113.97M104.20M103.25M
Current Liabilities --11.60M-30.25M45.03M34.92M30.64M
Long Term Debt --29.19M-52.71M53.01M53.31M55.58M
Total Debt ----68.59M70.30M69.65M71.86M
Total Equity 5.95M3.16M776.00K-60.53M137.94M112.89M87.33M
Shares Outstanding ----55.63M61.75M62.39M64.03M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -7.67M-4.49M--30.65M-34.58M-37.17M-15.97M
Investing Cash Flow -1.21M-1.07M--76.52M-81.30M35.38M13.25M
Financing Cash Flow 19.74M11.50M-20.81M109.38M160.00K2.08M
Capital Expenditure -1.21M-1.07M--14.84M-11.46M-11.59M-13.52M
Free Cash Flow -8.88M-5.56M--45.49M-46.03M-48.76M-29.49M
Net Change in Cash ----86.36M-6.49M-1.63M-642.00K

Ratios (Annual)

Figures in %.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 80.6%78.3%-82.0%81.2%80.4%79.8%
Operating Margin % -9.0%1.5%--24.6%-27.5%-26.6%-25.5%
Net Margin % -10.8%-6.4%--30.2%-26.5%-26.6%-27.7%
ROE % -134.9%-472.7%--70.7%-35.9%-49.4%-67.6%
ROCE % -2.8%--27.1%-24.9%-30.6%-33.9%

Shareholding Pattern

Insiders
25.43%
Institutions
57.10%
Public Float
76.57%

Top Institutional Holders

#Holder% HeldSharesValue
1 Armistice Capital, LLC 9.81% 6.36M $22.02M
2 Gagnon Securities, LLC 8.02% 5.20M $18.00M
3 Blackrock Inc. 5.15% 3.34M $11.56M
4 Bank of America Corporation 4.95% 3.21M $11.12M
5 CIBC Private Wealth Group, LLC 2.28% 1.48M $5.12M
6 Vanguard Capital Management LLC 2.25% 1.46M $5.06M
7 State Street Corporation 1.90% 1.24M $4.27M
8 CIBC Bancorp USA Inc. 1.88% 1.22M $4.22M
9 Millennium Management Llc 1.77% 1.15M $3.97M
10 AQR Capital Management, LLC 1.64% 1.06M $3.67M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TMCI

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks